Compare CBUS & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBUS | QSI |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.7M | 165.6M |
| IPO Year | 2017 | 2020 |
| Metric | CBUS | QSI |
|---|---|---|
| Price | $1.63 | $0.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $9.00 | $1.00 |
| AVG Volume (30 Days) | 92.9K | ★ 2.1M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.33 | 28.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,639,000.00 | $2,436,000.00 |
| Revenue This Year | $112.72 | N/A |
| Revenue Next Year | $83.18 | $618.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.09 | $0.69 |
| 52 Week High | $4.19 | $3.10 |
| Indicator | CBUS | QSI |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 49.69 |
| Support Level | $1.64 | $0.70 |
| Resistance Level | $1.82 | $0.79 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 82.76 | 57.55 |
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.